Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 3
3(60.0%)
Phase 2
1(20.0%)
Phase 1
1(20.0%)
5Total
Phase 3(3)
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06564818Phase 3Recruiting

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

Role: lead

NCT06793397Phase 3Recruiting

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Role: lead

NCT06605105Phase 3Enrolling By Invitation

Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

Role: lead

NCT06051721Phase 2Active Not Recruiting

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)

Role: lead

NCT05385783Phase 1Completed

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

Role: lead

All 5 trials loaded